Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ENLV.TA
- Price
- 361.90
- Stock movement up
- +9.70 (2.75%)
- Company name
- Enlivex Therapeutics Ltd
- Exchange
- (TA ,
- Currency
- ILA )
- Sector
- Healthcare >Biotechnology
- Market cap
- 7.96B
- Ent value
- 7.96B
- Price/Sales
- -
- Price/Book
- 278.62
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -31.13%
- 1 year return
- -75.68%
- 3 year return
- -40.18%
- 5 year return
- -34.81%
- 10 year return
- -
Last updated: 2025-04-05
DIVIDENDS
ENLV.TA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 278.62 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 21.99M |
| EPS (TTM) | -1.07 |
| FCF per share (TTM) | -0.82 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -18.66M |
| Net income (TTM) | -22.29M |
| EPS (TTM) | -1.07 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 3.75M |
| Net receivables | 0.00 |
| Total current assets | 28.57M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 5.05M |
| Total assets | 31.90M |
| Accounts payable | 303.00K |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 2.84M |
| Total liabilities | 3.34M |
| Shareholder's equity | 28.56M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -17.02M |
| Capital expenditures (TTM) | 95.00K |
| Free cash flow (TTM) | -17.12M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -78.05% |
| Return on Assets | -69.88% |
| Return on Invested Capital | -78.05% |
| Cash Return on Invested Capital | -59.93% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 352.20 |
| Daily high | 365.00 |
| Daily low | 345.00 |
| Daily Volume | 38K |
| All-time high | 14150.00 |
| 1y analyst estimate | - |
| Beta | 1.10 |
| EPS (TTM) | -1.07 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| ENLV.TA | S&P500 | |
| Current price drop from All-time high | -97.44% | -12.44% |
| Highest price drop | -97.51% | -56.47% |
| Date of highest drop | 2 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -84.53% | -11.07% |
| Avg time to new high | 117 days | 12 days |
| Max time to new high | 1359 days | 1805 days |
COMPANY DETAILS
Marketcap
7.96B
Marketcap category
Mid-cap
Description
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
Israel
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found